Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Humans are perhaps evolutionarily engineered to get deeply addicted to sugar, as it not only provides energy but also helps in storing fats, which helps in survival during starvation. Additionally, sugars (glucose and fructose) stimulate the feel‐good factor, as they trigger the secretion of serotonin and dopamine in the brain, associated with the reward sensation, uplifting the mood in general. However, when consumed in excess, it contributes to energy imbalance, weight gain, and obesity, leading to the onset of a complex metabolic disorder, generally referred to as diabetes. Type 2 diabetes mellitus (T2DM) is one of the most prevalent forms of diabetes, nearly affecting all age groups. T2DM is clinically diagnosed with a cardinal sign of chronic hyperglycemia (excessive sugar in the blood). Chronic hyperglycemia, coupled with dysfunctions of pancreatic β‐cells, insulin resistance, and immune inflammation, further exacerbate the pathology of T2DM. Uncontrolled T2DM, a major public health concern, also contributes significantly toward the onset and progression of several micro‐ and macrovascular diseases, such as diabetic retinopathy, nephropathy, neuropathy, atherosclerosis, and cardiovascular diseases, including cancer. The current review discusses the epidemiology, causative factors, pathophysiology, and associated comorbidities, including the existing and emerging therapies related to T2DM. It also provides a future roadmap for alternative drug discovery for the management of T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“The Warburg effect partially explains the mechanism by which hyperglycemia promotes tumor development (Avogaro 2024; Zhu and Qu 2022; Warburg 1956).”
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“The International Diabetes Federation (IDF) has predicted that the number of diabetic patients is going to rise to 783 million, with estimated health expenditures exceeding US$1054 billion by 2045 (Magliano and Boyko 2022; Saeedi et al. 2019).”
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985 · cited 1×
“Literature evidence that, on average, ~35% of all diabetic patients suffer from some form of vision-related complications (Yau et al. 2012; Steinmetz et al. 2021).”
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Oxidative stress, aging, and diseases
Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s158513 · Cited by 3,979 · cited 1×
“Oxidative stress causes SERCA inhibition and low expression of antioxidant enzymes in pancreatic islets, leading to the accumulation of interconnected plasma lipids and lipoprotein anomalies that further alleviate diabetic complications (Liguori et al. 2018; Dinić et al. 2022).”
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“Interestingly, literature evidences that exposure to the microbiota of obese individuals can lead to obesity in lean individuals (Ridaura et al. 2013).”
Steinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189 · cited 1×
“Literature evidence that, on average, ~35% of all diabetic patients suffer from some form of vision-related complications (Yau et al. 2012; Steinmetz et al. 2021).”
Gut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115 · cited 1×
“On the other hand, it is observed that relatively fewer SCFAs are produced by the gut microbiota of T2DM patients who are also obese (Crudele et al. 2023; Ruze et al. 2023; Karlsson et al. 2013).”
Mechanisms, regulation and functions of the unfolded protein response
Hetz, C., Zhang, K., & Kaufman, R. J. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0250-z · Cited by 2,666
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Globally, an estimated 32% (Einarson et al. 2018; Joseph et al. 2022) of T2DM patients suffer from CVDs such as ischemic heart disease, heart failure, stroke, coronary artery disease (CAD), and peripheral artery disease, all of which have a high mortality rate.”
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“Furthermore, GLP-1RAs cause nausea, headache, and diarrhea, including injection site reactions (Nauck, Quast, et al. 2021; Lyseng-Williamson 2019; Sodhi et al. 2023; Alves et al. 2012).”
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Skeletal muscle energy metabolism during exercise
Hargreaves, M., & Spriet, L. L. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0251-4 · Cited by 1,408 · cited 1×
“Within muscle cells, 15% of the absorbed glucose is liberated as glycolytic intermediates, such as lactate and alanine, while 50% undergoes oxidation and 35% is stored as glycogen (Hargreaves and Spriet 2020).”
The genetics of obesity: From discovery to biology
Loos, R. J. F., & Yeo, G. S. H. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00414-z · Cited by 1,291
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192 · cited 2×
“Generally, as per the guidelines (Buse et al. 2020), a combination of metformin and DPP-4i is initially recommended as T2DM therapy for sustain-ably controlling hyperglycemia for a longer duration.”
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Zatterale, F., Longo, M., Naderi, J., Raciti, G. A., Desiderio, A., Miele, C., & Beguinot, F. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01607 · Cited by 1,180 · cited 1×
“…lead to the differentiation of CD4+ cells into Th17 cells, which release IL-17F and IL-17A, further stimulating TNF-α production and ultimately contributing to systemic inflammation leading to insulin resistance (Blaszczak et al. 2021; Zatterale et al. 2020; Matarese 2023; Li, Shao, et al. 2021).”
Leptin and Obesity: Role and clinical implication.
Obradovic, M., Sudar-Milovanovic, E., Soskic, S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T., & Isenovic, E. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.585887 · Cited by 1,121 · cited 1×
“For instance, the epigenetic state of the adiponectin (ADIPOQ) (Kim et al. 2015; Donato 2023) as well as leptin (LEP) genes are linked to obesity (Obradovic et al. 2021).”
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Myelination and support of axonal integrity by glia
Nave, K.-A. (2010) · Nature · doi:10.1038/nature09614 · Cited by 1,062 · cited 1×
“Diabetic neuropathy is another severe microvascular complication caused by nerve damage due to impairment of the myelin sheath and Schwann cells, leading to axonal atrophy and apoptosis (Gonzalez-Gonzalez et al. 2020; Nave 2010; Sherman and Brophy 2005).”
Adipose tissue and insulin resistance in obese
Ahmed, B., Sultana, R., & Greene, M. W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111315 · Cited by 1,047
Beta Cell Dysfunction and Insulin Resistance
Cerf, M. E. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00037 · Cited by 964 · cited 1×
“…and insulin production exhaust the β-cell (Figure 7), which further combined with lipotoxicity, glucolipo-toxicity, and glucotoxicity, lead to β-cell oxidative stress and ER stress, resulting in β-cell dysfunction, apoptosis, and loss of β-cell mass (Li et al. 2008; Son and Accili 2023; Cerf 2013).”
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · cited 1×
“…the buildup of ectopic IMCL and the suppression of muscle insulin signaling by DAG/PKCθ redirects consumed glucose to the liver, where the simultaneous presence of postprandial hyperinsulin-emia and hyperglycemia elevates de novo lipogenesis in the liver (Smith et al. 2020; Li, Chi, et al. 2022).”
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
van Sloten, T. T., Sedaghat, S., Carnethon, M. R., Launer, L. J., & Stehouwer, C. D. A. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30405-x · Cited by 702
Mechanisms of axon ensheathment and myelin growth
Sherman, D. L., & Brophy, P. J. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1743 · Cited by 668
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Lee, Y. S., Kim, J.-W., Osborne, O., Oh, D. Y., Sasik, R., Schenk, S., Chen, A., Chung, H., Murphy, A., Watkins, S. M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.012 · Cited by 598
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications
Caturano, A., D’Angelo, M., Mormone, A., Russo, V., Mollica, M. P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080420 · Cited by 579
DeFuria, J., Belkina, A. C., Jagannathan-Bogdan, M., Snyder-Cappione, J., Carr, J. D., Nersesova, Y. R., Markham, D., Strissel, K. J., Watkins, A. A., Zhu, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215840110 · Cited by 521
A clinical perspective of obesity, metabolic syndrome and cardiovascular disease
Han, T. S., & Lean, M. E. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016633371 · Cited by 500
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Epidemiology and management of gestational diabetes
Sweeting, A., Hannah, W., Backman, H., Catalano, P., Feghali, M., Herman, W. H., Hivert, M.-F., Immanuel, J., Meek, C., Oppermann, M. L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00825-0 · Cited by 431
A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes
Moltke, I., Grarup, N., Jørgensen, M. E., Bjerregaard, P., Treebak, J. T., Fumagalli, M., Korneliussen, T. S., Andersen, M. A., Nielsen, T. S., Krarup, N. T., et al. (2014) · Nature · doi:10.1038/nature13425 · Cited by 418 · cited 1×
“The TBC1 domain family member 4 (TBC1D4) protein that continuously deactivates Rab GTPase (Rab8A and Rab13) involved in vesicle mobilization is a key regulator of glucose regulation in both muscle cells and adipose tissues (Moltke et al. 2014).”
Artificial intelligence in diabetes management: Advancements, opportunities, and challenges
Guan, Z., Li, H., Liu, R., Cai, C., Liu, Y., Li, J., Wang, X., Huang, S., Wu, L., Liu, D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101213 · Cited by 412 · cited 1×
“AI-powered algorithms have demonstrated exceptional accuracy in predicting blood glucose fluctuations, enabling proactive insulin adjustments and personalized treatment plans (Guan et al. 2023).”
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia
Sylow, L., Tokarz, V. L., Richter, E. A., & Klip, A. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.020 · Cited by 366 · cited 1×
“On the other hand, Rab8A promotes the translocation of FFA transporters (CD36, FATP1/4, FATP, and FABPpm) for long-chain fatty acid (LCFA) uptake (Sylow et al. 2021).”
Resolving the paradox of hepatic insulin resistance
Santoleri, D., & Titchenell, P. M. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.016 · Cited by 336 · cited 1×
“…where periportal and perivenous hepatocytes perform distinct functions, and any dysregulation of this compartmentalization contributes to the overall metabolic dysregulation observed in insulin-resistant states (da Silva Rosa et al. 2020; Santoleri and Titchenell 2019; Mastrototaro and Roden 2021).”
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270
Gut microbiota in the pathogenesis and therapeutic approaches of diabetes
Crudele, L., Gadaleta, R. M., Cariello, M., & Moschetta, A. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104821 · Cited by 251
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243 · cited 1×
“Therefore, therapeutic regimens collectively targeting DPP4 and GLP-1 receptor signaling have been highly desirable for managing T2DM (Campbell et al. 2023; Newsome and Ambery 2023; Drucker and Holst 2023; Nauck, Quast, et al. 2021).”
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231 · cited 14×
“For instance, the commercial production of the current long-chain GLP-1RAs is not cost-effective, whereas DPP-4is are more expensive than sulfonylureas.”
InfluentialIncretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
The dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194 · cited 1×
“…as microcrystal-line arrays in the granules as zinc-complexed hexamers until its secretion from pancreatic β-cells is triggered by high glucose concentration, including other triggers like amino acids, hormones, and fatty acids (Boland et al. 2017; Jones and Persaud 2024; Wijesekara et al. 2010).”
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Renal Gluconeogenesis: An Underestimated Role of the Kidney in Systemic Glucose Metabolism
Legouis, D., Faivre, A., Cippà, P. E., & de Seigneux, S. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa302 · Cited by 151
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149 · cited 2×
“…dapagliflozin) and dopamine D 2 agonists (DD2RA: bromocriptine) reduce renal glucose reabsorption and also promote euglycemia by increasing the amount of sugar excretion through urine (Padhi et al. 2020; Guo et al. 2024; Su et al. 2024; Majety et al. 2023; Campbell et al. 2023; Dahlén et al. 2022).”
Hepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
Jacobsen, L. M., Bocchino, L., Evans-Molina, C., DiMeglio, L., Goland, R., Wilson, D. M., Atkinson, M. A., Aye, T., Russell, W. E., Wentworth, J. M., et al. (2020) · Diabetologia · doi:10.1007/s00125-019-05047-w · Cited by 133 · cited 2×
“Islet cell autoantibodies, autoantibodies to glutamic acid decarboxylase (GAD), insulin, tyrosine phosphatases IA-2 and IA-2b, and zinc transporter ZnT8 are the serum autoimmune biomarkers in T1DM (Jacobsen et al. 2020; Herold et al. 2024).”
Besse-Patin, A., Jeromson, S., Levesque-Damphousse, P., Secco, B., Laplante, M., & Estall, J. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815150116 · Cited by 124
da Silva Rosa, S. C., Martens, M. D., Field, J. T., Nguyen, L., Kereliuk, S. M., Hai, Y., Chapman, D., Diehl-Jones, W., Aliani, M., West, A. R., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1821548 · Cited by 117 · cited 1×
“However, the hyper-accumulation of Nix in lipotoxic conditions leads to insulin resistance by activating mTORC-p7s6, which phosphorylates the serine residue of IRS1, thereby inhibiting the insulin signaling cascade (da Silva Rosa et al. 2020, 2021).”
Adaptation to chronic ER stress enforces pancreatic β-cell plasticity
Chen, C.-W., Guan, B.-J., Alzahrani, M. R., Gao, Z., Gao, L., Bracey, S., Wu, J., Mbow, C. A., Jobava, R., Haataja, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32425-7 · Cited by 116
Li, N., Frigerio, F., & Maechler, P. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360930 · Cited by 114
An update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
Inside the β Cell: Molecular Stress Response Pathways in Diabetes Pathogenesis
Kulkarni, A., Muralidharan, C., May, S. C., Tersey, S. A., & Mirmira, R. G. (2022) · Endocrinology · doi:10.1210/endocr/bqac184 · Cited by 95
Bergenstal, R. M., Johnson, M., Passi, R., Bhargava, A., Young, N., Kruger, D. F., Bashan, E., Bisgaier, S. G., Isaman, D. J. M., & Hodish, I. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30368-x · Cited by 88 · cited 1×
“Studies suggest that combining automated insulin titration tools with support from health-care professionals can result in better blood sugar control in patients with T2DM, compared to relying solely on healthcare professionals (Bergenstal et al. 2019).”
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87
Jaiswal, N., Gavin, M., Loro, E., Sostre‐Colón, J., Roberson, P. A., Uehara, K., Rivera‐Fuentes, N., Neinast, M., Arany, Z., Kimball, S. R., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12846 · Cited by 79
AI-based diabetes care: risk prediction models and implementation concerns
Wang, S. C. Y., Nickel, G., Venkatesh, K. P., Raza, M. M., & Kvedar, J. C. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01034-7 · Cited by 64
Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15150 · Cited by 60
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
Cited by
Nuñez-Selles, A. J., Nuñez-Musa, R. A., & Guillen-Marmolejos, R. A. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1611842 · Cited by 51
Metadata
- Authors
- Singh, A., Shadangi, S., Gupta, P. K., & Rana, S.
- Venue
- Comprehensive Physiology
- Publisher
- Wiley
- Published
- 2025-02
- Volume
- 15
- Issue
- 1
- Pages
- e70003-e70003
- ISSN
- 2040-4603 (ISSN-L)
- OpenAlex
- W4407829292
- Cited by
- 163
- References
- 74
- FWCI
- 97.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.